Related references
Note: Only part of the references are listed.Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2010)
A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations
Aiyi Liu et al.
CLINICAL TRIALS (2010)
A Bayesian adaptive design with biomarkers for targeted therapies
Jens C. Eickhoff et al.
CLINICAL TRIALS (2010)
Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials
Sue-Jane Wang et al.
CLINICAL TRIALS (2010)
Clinical trials for predictive medicine: new challenges and paradigms
Richard Simon
CLINICAL TRIALS (2010)
The efficiency of clinical trial designs for predictive biomarker validation
K. Y. Young et al.
CLINICAL TRIALS (2010)
Bayesian adaptive randomization designs for targeted agent development
J. Jack Lee et al.
CLINICAL TRIALS (2010)
Adjusted significance levels for subgroup analyses in clinical trials
Bart Spiessens et al.
CONTEMPORARY CLINICAL TRIALS (2010)
Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
INTERESTing Biomarker to Select IDEAL Patients for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Yes, for EGFR Mutation Analysis, Others, I PASS
Ramaswamy Govindan
JOURNAL OF CLINICAL ONCOLOGY (2010)
Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for Molecular Profiling of Individual Patients With Advanced Solid Tumors?
James H. Doroshow
JOURNAL OF CLINICAL ONCOLOGY (2010)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Bryan T. J. Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gene-expression-based prognostic assays for breast cancer
Chungyeul Kim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Molecular markers to individualize adjuvant therapy for colon cancer
Tara Gangadhar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
What should physicians look for in evaluating prognostic gene-expression signatures?
Jyothi Subramanian et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Biomarkers and surrogate end points-the challenge of statistical validation
Marc Buyse et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology
Richard Simon
PERSONALIZED MEDICINE (2010)
Optimizing Trial Design Sequential, Adaptive, and Enrichment Strategies
Cyrus Mehta et al.
CIRCULATION (2009)
Effective Incorporation of Biomarkers into Phase II Trials
Lisa M. McShane et al.
CLINICAL CANCER RESEARCH (2009)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
Sumithra J. Mandrekar et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Sumithra J. Mandrekar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment
Sheila E. Taube et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
MOLECULAR ORIGINS OF CANCER Gene-Expression Signatures in Breast Cancer
Christos Sotiriou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
Werner Brannath et al.
STATISTICS IN MEDICINE (2009)
A flexible strategy for testing subgroups and overall population
Mohamed Alosh et al.
STATISTICS IN MEDICINE (2009)
Genomic advances and their impact on clinical trial design
Sumithra J. Mandrekar et al.
GENOME MEDICINE (2009)
Statistical Issues in Translational Cancer Research
Stephen L. George
CLINICAL CANCER RESEARCH (2008)
The Use of Genomics in Clinical Trial Design
Richard Simon
CLINICAL CANCER RESEARCH (2008)
Randomized phase III clinical trial designs for targeted agents
Antje Hoering et al.
CLINICAL CANCER RESEARCH (2008)
A predictive probability design for phase II cancer clinical trials
J. Lack Lee et al.
CLINICAL TRIALS (2008)
Bayesian adaptive design for targeted therapy development in lung cancer - a step toward personalized medicine
Xian Zhou et al.
CLINICAL TRIALS (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Soonmyung Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints
Marissa N. Lassere
STATISTICAL METHODS IN MEDICAL RESEARCH (2008)
Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer
Lajos Pusztai et al.
CLINICAL CANCER RESEARCH (2007)
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Wenyu Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
Sue-Jane Wang et al.
PHARMACEUTICAL STATISTICS (2007)
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression:: A phase III trial in non-small-cell lung cancer
Manuel Cobo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
New challenges for 21st century clinical trials
Richard Simon
CLINICAL TRIALS (2007)
An adaptive Simon Two-Stage Design for phase 2 studies of targeted therapies
Cheryl L. Jones et al.
CONTEMPORARY CLINICAL TRIALS (2007)
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
Jan Bogaerts et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
Marc Buyse et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Clinical trials design and treatment tailoring: General principles applied to breast cancer research
P. Therasse et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Statistical evaluation of biomarkers as surrogate endpoints: a literature review
CJ Weir et al.
STATISTICS IN MEDICINE (2006)
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
B Freidlin et al.
CLINICAL CANCER RESEARCH (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
JR Zalcberg et al.
EUROPEAN JOURNAL OF CANCER (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
On the efficiency of targeted clinical trials
A Maitournam et al.
STATISTICS IN MEDICINE (2005)
Evaluating the efficiency of targeted designs for randomized clinical trials
R Simon et al.
CLINICAL CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Issues in clinical trial design for tumor marker studies
D Sargent et al.
SEMINARS IN ONCOLOGY (2002)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint
R Mick et al.
CONTROLLED CLINICAL TRIALS (2000)
Share Paper
